Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lingze tablets plus doxazosin mesylate for benign prostatic hyperplasia
ChiCTR2300071954Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Gannan Medical University
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Lingze and doxazosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by First Affiliated Hospital of Gannan Medical University. Primary endpoint: IPSS score difference. Planned start May 2023; status: not yet recruiting.
02
Drugs
Lingzedoxazosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on ChiCTR2300071954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071954.